Healthcare Industry News:  Frank Condella 

Biopharmaceuticals Personnel

 News Release - July 20, 2016

Juniper Pharmaceuticals Appoints Alicia Secor President and Chief Executive Officer

BOSTON, July 20, 2016 -- (Healthcare Sales & Marketing Network) -- Juniper Pharmaceuticals, Inc. (JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced that its Board of Directors has appointed veteran healthcare executive Alicia Secor as its President and CEO, effective August 1, 2016. Ms. Secor will also be appointed to the Board of Directors.

"Alicia Secor is a proven leader, with an impressive combination of vision, passion, and experience building and managing pharmaceutical businesses," said Jim Geraghty, Chairman of Juniper's Board. "She brings directly relevant experience in leading the development of new products through to regulatory approval and commercialization, which is a critical part of Juniper's go-forward strategy."

Ms. Secor' brings more than 25 years' of leadership experience as a life sciences executive, with a track record in leading businesses and advancing products from clinical development through regulatory approval, commercialization, and global expansion across several therapeutic areas. She joins Juniper from Zafgen, Inc., where she served as Chief Commercial Officer and played a key role in advancing the company to a Phase 3 pre-commercialization status.

Previously Ms. Secor served 15 years at Genzyme Corporation in diverse leadership roles, most recently as the Global General Manager for the Metabolic Disease Business. During her tenure at Genzyme, Ms. Secor led fully integrated businesses, successfully launching products and achieving sustained revenue growth. Ms. Secor spearheaded several strategic transactions and built high performance teams, resulting in consistent growth and profitability across multiple Genzyme businesses including biomaterials, surgical devices, and injectable therapeutics.

"I am excited to join Juniper at such an important time in the Company's evolution," said Ms. Secor. "I look forward to working with Juniper's high caliber leadership team and dedicated employees to achieve further growth at Juniper Pharma Services and support the growing Crinone franchise while accelerating the development and commercialization of therapeutics focused on significant unmet needs in women's health care in the U.S. and around the world."

"We are confident that Alicia is the right person to lead Juniper going forward, and to execute the Company's strategy to develop and commercialize important products for women's health. She joins a dedicated team that is advancing a pipeline of high-value product candidates poised to create long-term shareholder value, which she is ideally suited to take forward," Mr. Geraghty concluded.

Prior to Genzyme, Ms. Secor held positions at Alkermes in business development, at Centocor (a Johnson & Johnson Company) in clinical and commercial operations. She began her career at Pfizer as a hospital-based sales representative.

Ms. Secor received an M.B.A. from Northeastern University, and a B.S. in Healthcare Administration from the University of New Hampshire

Ms. Secor succeeds Frank Condella, who announced his intent to retire as Juniper's President and CEO earlier this year. As previously announced, Mr. Condella will remain on the Board as a non-executive director, and will consult to the Company for an interim period to ensure an orderly transition.

Source: Juniper Pharmaceuticals

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.